VERhO
Optimizing Health Care for Patients with Rheumatism
Rheumatoid arthritis (short: rheumatism) is one of the most common chronic inflammatory diseases. In Germany approximately 800.000 people suffer from rheumatism. Characteristic is an uncontrolled inflammation of the synovial membrane (synovitis), which if not treated does not only cause chronic pain but also a progressive deterioration of joints, together with loss of function and disablement.
The health care model “VERO” will contribute to optimize the use of pharmaceuticals especially in the high price range by providing patients with necessary pharmaceuticals and by avoiding an unnecessary or rather unnecessarily highly dosed use of pharmaceuticals. Another key area is to record the patients’ individual needs and to treat them appropriately in doctor-patient conversations. Through doctor-patient conversation it becomes possible to recognize pharmaceutical-related problems and to develop strategic solutions.
Prof. Dr. Tom Stargardt was responsible for the health economic evaluation of the project. The evaluator cooperated closely with experts from clinical research. The effects of de-escalation on various disease parameters were evaluated in a controlled, prospective study. In addition, an evaluation of the costs of care for insured persons of the "Techniker Krankenkasse" took place. The results of the evaluation are expected to be published in the first quarter of 2022.
The project "VERhO - optimising care for people with rheumatism" was funded by the Innovation Fund of the Federal Joint Committee (Innovation Funds for the Promotion of New Forms of Health Care). Further information can be found here.
Project Information VERhO
Principal:
Innovation Committee at the Federal Joint Committee (Innovation Funds for the Promotion of New Forms of Health Care (§§92a article 1 and 92b SGB V), DLR project sponsor
Project Term:
2017-2021
Transfer Output:
The control of success as a part of the project is the basis for the decision about the use in the health care practice beyond the project.
Transfer Target Group:
- Decision-makers at health insurances